Icon launches new electronic financial disclosure form software

Icon estimates the software can cut costs more than 50% compared to traditional form managment methods. (Icon)

Icon has launched a new, paperless solution for managing the clinical investigator financial disclosure forms mandated by the FDA.

The Dublin-based contract research organization’s Firecrest Financial Disclosure software allows sponsors to electronically gather, distribute, track and manage completion of the forms, required under 21 CFR Part 54, ahead of the study start-up process.

Icon hopes the system will lower the risks of regulatory noncompliance and reduce administrative costs compared to traditional distribution and tracking, the company said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We estimate the solution is capable of delivering savings in excess of 50% when compared to traditional methods, while also contributing to the environmental sustainability targets of our clients,” said Mark Connolly, vice president for Firecrest systems at Icon.

Icon developed the software to address ongoing compliance challenges in the industry due to incomplete forms, the company said.

Icon first acquired Firecrest Clinical in 2011, and now offers a suite of web-based software including electronic consent forms and biometrics, patient prescreening, document tracking and site staff training and guides.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.